 Home > Active Ingredient News > Antitumor Therapy > JAMA Oncol: Efficacy and safety of carotuximab combined with pazopanib in the treatment of advanced angiosarcoma

JAMA Oncol: Efficacy and safety of carotuximab combined with pazopanib in the treatment of advanced angiosarcoma

 Last Update: 2022-04-24
 Source: Internet
 Author: User

Tags

h2o plus

anderson advanced ingredients

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Angiosarcoma is a rare subtype of sarcoma with a poor prognosis

Blood vessel

This study aimed to determine whether carotuximab plus pazopanib could prolong progression-free survival in patients with advanced angiosarcoma compared with pazopanib monotherapy

Whether carotuximab plus pazopanib prolongs progression-free survival in patients with advanced angiosarcoma compared with pazopanib monotherapy

This is an international, multicenter, open-label, parallel-group, phase 3 randomized trial recruiting patients 18 years of age and older with advanced angiosarcoma and randomized 1:1 to receive either pazopanib monotherapy or Carotuximab combined with pazopanib

A total of 123 patients were recruited, of whom 114 were included in the analysis (53 in the pazopanib monotherapy group and 61 in the combination group), including 69 (61%) women, with a median age of 68 years; 57 (50%) were skin lesions, and 32 (28%) were previously untreated

Median PFS was 4.

hypertension

Carotuximab plus pazopanib did not improve progression-free survival in patients with advanced angiosarcoma compared with pazopanib monotherapy

Original source:

Jones RL, Ravi V, Brohl AS, et al.

JAMA

's message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Dacarbazine CAS 4342-03-4 for Scientific Research Chemical Reagents Use only

CAS No.: 4342-03-4

Pharmacy Grade

$4-5/G FOB

Lapatinib 99% white powder CAS231277-92-2 bulk Lapatinib

CAS No.: 231277-92-2

Pharmacy Grade

$88-98/KG FOB

Mitomycin C

CAS No.: 50-07-7

Industrial Grade

$0.1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.